BRPI0810959A2 - "proteína l1 do hpv11, polinucleotídeo, vetor, célula, composição, partícular semelhante ao vírus (vlp) hp11, método para produzir uma proteína l1 do hpv,vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína método para prevenção de condiloma acuminado ou infecções por hpv e método para prevenção de condiloma acuminado ou infecções por hpv. - Google Patents

"proteína l1 do hpv11, polinucleotídeo, vetor, célula, composição, partícular semelhante ao vírus (vlp) hp11, método para produzir uma proteína l1 do hpv,vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína método para prevenção de condiloma acuminado ou infecções por hpv e método para prevenção de condiloma acuminado ou infecções por hpv.

Info

Publication number
BRPI0810959A2
BRPI0810959A2 BRPI0810959-1A BRPI0810959A BRPI0810959A2 BR PI0810959 A2 BRPI0810959 A2 BR PI0810959A2 BR PI0810959 A BRPI0810959 A BR PI0810959A BR PI0810959 A2 BRPI0810959 A2 BR PI0810959A2
Authority
BR
Brazil
Prior art keywords
protein
prevention
hpv
hpv infections
condyloma
Prior art date
Application number
BRPI0810959-1A
Other languages
English (en)
Inventor
Jun Zhang
Jin Wang
Chunyan Yang
Ying Gu
Shaowei Li
Ningshoa Xia
Original Assignee
Xiamen University E Outro
Beijing Wantai Biological Pharmacy Entpr Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen University E Outro, Beijing Wantai Biological Pharmacy Entpr Co Ltd filed Critical Xiamen University E Outro
Publication of BRPI0810959A2 publication Critical patent/BRPI0810959A2/pt
Publication of BRPI0810959B1 publication Critical patent/BRPI0810959B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0810959-1A 2007-05-29 2008-05-29 Proteína l1 do hpv11, polinucleotídeo, vetor, célula, composição, partícula do tipo vírus (vlp) hpv11, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções por hpv e método para produzir uma vacina para prevenção de condiloma acuminado ou infecções por hpv BRPI0810959B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200710105763.2 2007-05-29
CN200710105763 2007-05-29
PCT/CN2008/001049 WO2008145020A1 (fr) 2007-05-29 2008-05-29 Protéine l1 tronquée du papillomavirus 11 humain

Publications (2)

Publication Number Publication Date
BRPI0810959A2 true BRPI0810959A2 (pt) 2015-07-21
BRPI0810959B1 BRPI0810959B1 (pt) 2021-06-29

Family

ID=40074566

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810959-1A BRPI0810959B1 (pt) 2007-05-29 2008-05-29 Proteína l1 do hpv11, polinucleotídeo, vetor, célula, composição, partícula do tipo vírus (vlp) hpv11, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções por hpv e método para produzir uma vacina para prevenção de condiloma acuminado ou infecções por hpv

Country Status (6)

Country Link
US (3) US9533035B2 (pt)
EP (3) EP2154148B1 (pt)
CN (1) CN101343314B (pt)
BR (1) BRPI0810959B1 (pt)
DK (3) DK2910566T5 (pt)
WO (1) WO2008145020A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428555B2 (en) * 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
WO2008134935A1 (en) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
DK2154149T3 (da) * 2007-05-29 2019-10-14 Univ Xiamen En trunkeret l1-protein af human papillomavirus 6
WO2012000454A1 (zh) 2010-07-02 2012-01-05 厦门大学 截短的人乳头瘤病毒52型l1蛋白
CN102229660B (zh) * 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CN105177025B (zh) * 2013-12-03 2022-11-01 北京康乐卫士生物技术股份有限公司 18型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106831960B (zh) * 2015-12-04 2019-11-05 厦门大学 一种人乳头瘤病毒6型l1蛋白的突变体
JP6920694B2 (ja) * 2015-12-04 2021-08-18 シアメン ユニバーシティＸｉａｍｅｎ Ｕｎｉｖｅｒｓｉｔｙ ヒトパピローマウイルスタイプ１１のｌ１タンパク質の突然変異
CN114127095B (zh) * 2019-07-19 2024-04-09 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
CN114539363B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种c端改造的人乳头瘤病毒11型l1蛋白及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE492289T1 (de) * 1993-03-09 2011-01-15 Univ Rochester Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln
US20020193565A1 (en) * 1998-03-27 2002-12-19 Stanley Margaret Anne Antigen preparation and use
US6551597B1 (en) * 1999-03-18 2003-04-22 President & Fellows Of Harvard College Vaccine compositions for human papillomavirus
AP2004003021A0 (en) * 2001-08-31 2004-06-30 Univ Cape Town Vectors, constructs and transgenic plants for HPV-11 and HPV-16 L1 capsid protein.
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
AU2003228816A1 (en) * 2002-05-02 2003-11-17 Boyce Thompson Institute For Plant Research, Inc. Production of papillomavirus vaccines in plants
CN1293093C (zh) * 2002-08-30 2007-01-03 马润林 乳头瘤病毒衣壳蛋白的原核制备和应用
CN1683010A (zh) * 2005-02-06 2005-10-19 哈尔滨医科大学 人乳头瘤病毒型双价病毒样颗粒混合蛋白抗原及构建方法
CN101153280B (zh) * 2006-09-29 2015-08-19 厦门大学 从原核生物中纯化人乳头瘤病毒晚期蛋白l1的方法

Also Published As

Publication number Publication date
US9533035B2 (en) 2017-01-03
HK1124344A1 (zh) 2009-07-10
US20100291141A1 (en) 2010-11-18
EP2910566B1 (en) 2016-07-13
EP2154148A1 (en) 2010-02-17
EP2154148A4 (en) 2011-01-05
US20170065708A1 (en) 2017-03-09
HK1208473A1 (en) 2016-03-04
US9943586B2 (en) 2018-04-17
EP2910566A1 (en) 2015-08-26
WO2008145020A1 (fr) 2008-12-04
EP2154148B1 (en) 2016-06-22
US10537629B2 (en) 2020-01-21
DK2154148T3 (en) 2016-09-19
BRPI0810959B1 (pt) 2021-06-29
EP2907821B1 (en) 2016-12-28
CN101343314A (zh) 2009-01-14
EP2907821A1 (en) 2015-08-19
DK2910566T3 (en) 2016-10-24
CN101343314B (zh) 2015-11-25
DK2910566T5 (en) 2016-11-07
US20180207257A1 (en) 2018-07-26
DK2907821T3 (en) 2017-04-10

Similar Documents

Publication Publication Date Title
BRPI0810959A2 (pt) "proteína l1 do hpv11, polinucleotídeo, vetor, célula, composição, partícular semelhante ao vírus (vlp) hp11, método para produzir uma proteína l1 do hpv,vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína método para prevenção de condiloma acuminado ou infecções por hpv e método para prevenção de condiloma acuminado ou infecções por hpv.
BRPI0810951A2 (pt) Proteína l1 hpv6, polinucleotídeo, vetor, célula, composição, partícula semelhante ao vírus (vlp) hpv6, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções porhpv, uso da proteína, método para prevenção de condiloma acuminado ou infecções por hpv, método pra obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
Hirt et al. Trichomonas vaginalis pathobiology: new insights from the genome sequence
EP4215543A3 (en) Hpv-specific binding molecules
BRPI1014718A2 (pt) polipeptídeo do papiloma vírus humano, capsômero, partícula tipo vírus, composição imunogência, molécula de ácido nucléico, e, métodos para produzir o polipeptídeo, e, para preparar uma composição imunogênica
WO2008061243A3 (en) Respiratory syncytial virus-virus like particle (vlps)
EP1687329B8 (en) Optimized expression of hpv 58 l1 in yeast
EP1917033A4 (en) VIRUS LIKE PARTICLES AS PARAMYXOVIRUS VACCINES
WO2017040387A3 (en) Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
IL193397A0 (en) Hpv antigens, vaccine compositions, and related methods
WO2006075245A3 (en) Systems, methods, and compositions for detection of human papilloma virus in biological samples
WO2010001409A3 (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
WO2010101967A3 (en) Phosphothiophene and phosphothiazole hcv polymerase inhibitors
WO2008034388A8 (en) Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
WO2013006569A3 (en) Herpes virus vaccine and methods of use
WO2017192418A8 (en) Therapeutic hpv vaccine combinations
HUS1500061I1 (hu) A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
BRPI0818718B8 (pt) processo de preparo de uma composição de vacina compreendendo antígeno e adjuvante na forma de látex inverso de homopolímero do ácido acrílico
WO2008100290A3 (en) Recombinant rhinovirus vectors
BR112013000996A2 (pt) proteína l1 hpv58 truncada ou variante da mesma, ácido nucleíco isolado, vetor, célula hospedeira, partícula do tipo viral hpv58, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv58 truncada, método para preparar a partícula do tipo viral hpv58, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada por infecção hpv, e uso da proteína l1 hpv58 truncada ou variante da mesma
WO2010033619A3 (en) Systems, methods, and compositions for detection of human papilloma virus in biological samples
IL179138A0 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31,45, or 52
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
MX2014000522A (es) Composicion y metodo para tratar virus del papiloma humano (vph).
HK1196785A (en) Composition and method for treating hpv

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: XIAMEN UNIVERSITY E OUTRO (CN) ; XIAMEN INNOVAX BI

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.